Publish-box (todo)
Clinical Decision Support Work Group | Maturity Level: N/A | Standards Status: Informative | Compartments: No defined compartments |
Raw JSON (canonical form + also see JSON Format Specification)
Chemotherapy Regimen
{ "resourceType" : "PlanDefinition", "id" : "KDN5", "text" : { "status" : "additional", "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n \n <table style=\"width: 100%;\">\n \n <tr>\n \n <td>\n \n \n <div style=\"width: 200px; height: 100px; vertical-align: top;\">National Comprehensive Cancer Network</div>\n \n </td>\n \n <td>\n \n <h3>Chemotherapy Order Template</h3>\n \n <h1>Kidney Cancer</h1>\n \n <h2>Gemcitabine/CARBOplatin</h2>\n \n </td>\n \n <td style=\"text-align: right; vertical-align: top;\">KDN5</td>\n \n </tr>\n \n </table>\n \n <table style=\"width: 100%; border-top: 1px solid; border-bottom: 1px solid;\">\n \n <tr>\n \n <td style=\"width: 33%; border-right: 1px solid; vertical-align: top\">\n \n <h4>INDICATION:</h4>\n \n <p>Metastatic or Relapsed – Collecting Duct/Medullary Subtypes</p>\n \n </td>\n \n <td style=\"width: 34%; border-right: 1px solid; vertical-align: top\">\n \n <h4>REFERENCES:</h4>\n \n <ol>\n \n <li>\n <a href=\"http://www.example.org/professionals/physician_gls/PDF/kidney.pdf\">NCCN Guidelines® for Kidney Cancer. V.3.2015.</a>\n </li>\n \n <li>\n <a href=\"http://www.ncbi.nlm.nih.gov/pubmed?term=%22The+Journal+of+urology%22%5BJour%5D+AND+1698%5Bpage%5D+AND+2007%5Bpdat%5D+AND+Oudard+S%5Bauthor%5D\">Oudard S, et al. \n <em>J Urol</em>. 2007;177(5):1698-702.\n </a>\n <sup>\n \n <a href=\"http://www.example.org/OrderTemplates/PDF/appendix_E.pdf\">a</a>\n </sup>\n \n </li>\n \n </ol>\n \n </td>\n \n <td style=\"width: 33%; vertical-align: top\">\n \n <h4>NCCN SUPPORTIVE CARE:</h4>\n \n <ol>\n \n <li>\n \n <i>Emetic Risk:</i>\n \n <table>\n \n <tr>\n \n <td>Day 1</td>\n \n <td>Moderate</td>\n \n </tr>\n \n <tr>\n \n <td>Day 8</td>\n \n <td>Low</td>\n \n </tr>\n \n </table>\n \n </li>\n \n <li>\n \n <i>Fever Neutropenia Risk:</i>\n <br/>\n Refer to \n <a href=\"http://www.example.org/professionals/physician_gls/PDF/myeloid_growth.pdf\">NCCN Guidelines for Myeloid Growth Factors. V.2.2014</a>\n \n </li>\n \n </ol>\n \n </td>\n \n </tr>\n \n </table>\n \n \n <h4>CHEMOTHERAPY REGIMEN</h4>\n \n <p>\n \n <i>21-day cycle for 6 cycles</i>\n \n </p>\n \n <ul>\n \n <li>Gemcitabine 1250 mg/m\n <sup>2</sup> IV over 30 minutes on Days 1 and 8\n </li>\n \n <li>CARBOplatin AUC 5 IV over 30 minutes on Day 1</li>\n \n </ul>\n \n </div>" }, "contained" : [{ "resourceType" : "ActivityDefinition", "id" : "1111", "status" : "draft", "productCodeableConcept" : { "coding" : [{ "system" : "http://www.nlm.nih.gov/research/umls/rxnorm", "code" : "12574", "display" : "gemcitabine" }], "text" : "gemcitabine" }, "dosage" : [{ "text" : "1250 mg/m² IV over 30 minutes", "timing" : { "repeat" : { "duration" : 30, "durationUnit" : "min" } }, "route" : { "text" : "IV" }, "doseAndRate" : [{ "type" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/dose-rate-type", "code" : "ordered", "display" : "Ordered" }] }, "doseQuantity" : { "value" : 1250, "unit" : "mg/m²" } }] }] }, { "resourceType" : "ActivityDefinition", "id" : "2222", "status" : "draft", "productCodeableConcept" : { "coding" : [{ "system" : "http://www.nlm.nih.gov/research/umls/rxnorm", "code" : "40048", "display" : "Carboplatin" }], "text" : "CARBOplatin" }, "dosage" : [{ "text" : "AUC 5 IV over 30 minutes", "timing" : { "repeat" : { "duration" : 30, "durationUnit" : "min" } }, "route" : { "text" : "IV" }, "doseAndRate" : [{ "type" : { "coding" : [{ "system" : "http://terminology.hl7.org/CodeSystem/dose-rate-type", "code" : "ordered", "display" : "Ordered" }] }, "doseQuantity" : { "extension" : [{ "url" : "http://example.org/fhir/AUC-dose", "valueInteger" : 5 }] } }] }] }], "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg", "valueCode" : "cds" }], "identifier" : [{ "system" : "http://example.org/ordertemplates", "value" : "KDN5" }], "version" : "1", "name" : "GemcitabineCARBOplatin", "title" : "Gemcitabine/CARBOplatin", "type" : { "text" : "Chemotherapy Order Template" }, "status" : "draft", "experimental" : true, "publisher" : "HL7 International / Clinical Decision Support", "contact" : [{ "telecom" : [{ "system" : "url", "value" : "http://www.hl7.org/Special/committees/dss" }] }], "description" : "Gemcitabine/CARBOplatin", "useContext" : [{ "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString" : "A" }], "code" : { "system" : "http://example.org/fhir/CodeSystem/indications", "code" : "treamentSetting-or-diseaseStatus" }, "valueCodeableConcept" : { "text" : "Metastatic" } }, { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString" : "A" }], "code" : { "system" : "http://example.org/fhir/CodeSystem/indications", "code" : "disease-or-histology" }, "valueCodeableConcept" : { "text" : "Collecting Duct/Medullary Subtypes" } }, { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString" : "A" }], "code" : { "system" : "http://terminology.hl7.org/CodeSystem/usage-context-type", "code" : "focus" }, "valueCodeableConcept" : { "text" : "Kidney Cancer" } }, { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString" : "B" }], "code" : { "system" : "http://example.org/fhir/CodeSystem/indications", "code" : "treatmentSetting-or-diseaseStatus" }, "valueCodeableConcept" : { "text" : "Relapsed" } }, { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString" : "B" }], "code" : { "system" : "http://example.org/fhir/CodeSystem/indications", "code" : "disease-or-histology" }, "valueCodeableConcept" : { "text" : "Collecting Duct/Medullary Subtypes" } }, { "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/usagecontext-group", "valueString" : "B" }], "code" : { "system" : "http://terminology.hl7.org/CodeSystem/usage-context-type", "code" : "focus" }, "valueCodeableConcept" : { "text" : "Kidney Cancer – Collecting Duct/Medullary Subtypes - Metastatic" } }], "copyright" : "All rights reserved.", "approvalDate" : "2016-07-27", "lastReviewDate" : "2016-07-27", "author" : [{ "name" : "Lee Surprenant" }], "relatedArtifact" : [{ "type" : "derived-from", "display" : "NCCN Guidelines for Kidney Cancer. V.2.2016", "document" : { "url" : "http://www.example.org/professionals/physician_gls/PDF/kidney.pdf" } }, { "type" : "citation", "_type" : { "extension" : [{ "url" : "http://example.org/fhir/regimenReferenceType", "valueCode" : "a" }] }, "citation" : "Oudard S, et al. J Urol. 2007;177(5):1698-702", "document" : { "url" : "http://www.ncbi.nlm.nih.gov/pubmed/17437788" } }], "action" : [{ "selectionBehavior" : "exactly-one", "action" : [{ "selectionBehavior" : "all", "action" : [{ "groupingBehavior" : "sentence-group", "selectionBehavior" : "exactly-one", "action" : [{ "id" : "cycle-definition-1", "textEquivalent" : "21-day cycle for 6 cycles", "timingTiming" : { "repeat" : { "count" : 6, "duration" : 21, "durationUnit" : "d" } }, "action" : [{ "id" : "action-1", "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle", "extension" : [{ "url" : "day", "valueInteger" : 1 }, { "url" : "day", "valueInteger" : 8 }] }], "textEquivalent" : "Gemcitabine 1250 mg/m² IV over 30 minutes on days 1 and 8", "definitionCanonical" : "#1111" }, { "id" : "action-2", "extension" : [{ "url" : "http://hl7.org/fhir/StructureDefinition/timing-daysOfCycle", "extension" : [{ "url" : "day", "valueInteger" : 1 }] }], "textEquivalent" : "CARBOplatin AUC 5 IV over 30 minutes on Day 1", "relatedAction" : [{ "targetId" : "action-1", "relationship" : "concurrent-with-start" }], "definitionCanonical" : "#2222" }] }] }] }] }] }
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.
FHIR ®© HL7.org 2011+. FHIR R6 hl7.fhir.core#6.0.0-ballot2 generated on Mon, Aug 12, 2024 16:59+0800.
Links: Search |
Version History |
Contents |
Glossary |
QA |
Compare to R5 |
|
Propose a change